Cue Biopharma (CUE) Free Cash Flow (2017 - 2025)

Cue Biopharma has disclosed Free Cash Flow across 9 years of filings, most recently posting -$1.1 million for Q4 2025.

• Free Cash Flow for Q4 2025 came in at -$1.1 million, up 88.08% year-over-year; the trailing twelve-month figure through Dec 2025 was -$21.9 million (up 39.93% YoY), and the FY2025 annual result was -$21.9 million, up 39.93% from the prior year.
• Free Cash Flow came in at -$1.1 million for Q4 2025 at Cue Biopharma, up from -$9.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.1 million in Q4 2025 to a low of -$12.9 million in Q2 2022.
• The 5-year median for Free Cash Flow is -$9.9 million (2024), against an average of -$9.0 million.
• Peak annual rise in Free Cash Flow reached 91.79% in 2021, while the deepest fall reached 107.5% in 2021.
• Cue Biopharma's Free Cash Flow stood at -$10.6 million in 2021, then grew by 1.22% to -$10.5 million in 2022, then decreased by 4.21% to -$11.0 million in 2023, then gained by 17.59% to -$9.0 million in 2024, then surged by 88.08% to -$1.1 million in 2025.
• The last three Free Cash Flow figures came in at -$1.1 million (Q4 2025), -$9.0 million (Q3 2025), and -$3.4 million (Q2 2025), per Business Quant data.